Cardiovascular disease is a major cause of mortality worldwide. The advent of human-induced pluripotent stem cells (hiPSCs) technology have enabled the reliable generation of individual-derived cardiomyocytes (CMs) [1] . Together with improvements in CM isolation techniques in culture [2] and the increased scalability of CM production from hiPSCs [3], hiPSC-CMs hold great promises in cardiopathological disease modelling and autologous tissue transplantation. However, as it is widely known, hiPSC-CMs more closely resemble CMs in the embryonic or fetal stages, and are immature in terms of marker expressions, electrophysiological properties, ultrastructural features and metabolic signature. Pertaining to this last feature, immature CMs prefer to use glycolysis for their energy metabolism, as opposed to β-oxidation of fatty acids [4] . This immature phenotype of newly derived hiPSC-CMs limits their immediate applications, and a prolonged culture period necessary for better maturation is neither logistically nor economically ideal. A number of strategies have been employed to hasten the maturity of hiPSC-CMs, which includes the addition of thyroid hormone T3, the bioengineering of culture environment or scaffolds, the application of mechanical stimuli [5, 6] and other genetic/epigenetic manipulations [7] .
This palmitate-induced OCR in matured hiPSC-CMs is abolished by the fatty acid oxidation inhibitor etomoxir, but not by 2-deoxyglucose inhibition of glycolysis. Matured hiPSC-CMs thus appear much more capable of utilizing exogenous palmitate for energy than the control iPSC-CMs. Interestingly, assessments of glycolytic flux parameters via measurements of the extracellular acidification rate (ECAR) indicated that ECAR levels in terms of glycolysis, glycolytic capacity, and glycolytic reserve were all significantly higher in mature hiPSC-CMs. These mature hiPSC-CMs, despite their fatty acid utilizing capability, are thus not impaired in terms of glycolytic capacity, and could readily switch to glucose as an energy substrate when necessary.
The findings of Horikoshi and colleagues, as the authors claimed, showed that fatty acid-containing maturation medium can promote hiPSC-CMs to undergo maturation [8] . As the supplements used in the control and maturation medium are not equal, the authors were careful in pointing out the caveat of potential maturation enhancing roles by taurine, carnitine, and selenium. However, the authors' findings are indeed very much in line with a flurry of other recent reports indicating that fatty acids could enhance hiPSC-CMs maturation [9] [10] [11] . That a simple substitution of fatty acids for glucose in the culture medium could have such a significant maturation effect on hiPSC-CMs is certainly an encouraging advance. Clearly this change is easier and cheaper to implement compared to methods involving sophisticated scaffold engineering, constant mechanical stimulation, or complex genetic/epigenetic manipulations. A question that was not pointedly addressed by Horikoshi and colleagues in their report is the underlying mechanism as to how a fatty acid-enriched, no-glucose medium could induce hiPSC-CMs maturation. PPARα is known to play a critical role in cardiomyocyte maturation, and PPARα agonists have been shown to promote cardiomyocyte maturation [12, 13] . Furthermore, glucose is known to suppress the expression of PPARα [14] . As a fatty acid sensing transcriptional regulator [15] , PPARα's induction and activity by added fatty acids could thus conceivably underlie the transformation of immature iPSC-CMs towards a more mature phenotype.
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